Hsbc Holdings PLC Purchases New Position in Ralliant Corporation $RAL

Hsbc Holdings PLC acquired a new position in shares of Ralliant Corporation (NYSE:RAL) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 154,825 shares of the company’s stock, valued at approximately $11,433,000. Hsbc Holdings PLC owned approximately 0.14% of Ralliant as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Allworth Financial LP boosted its position in shares of Ralliant by 134.4% during the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after buying an additional 293 shares during the last quarter. Rothschild Investment LLC grew its holdings in Ralliant by 98.1% during the fourth quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock worth $31,000 after buying an additional 303 shares in the last quarter. Keybank National Association OH raised its position in Ralliant by 1.6% in the 4th quarter. Keybank National Association OH now owns 19,667 shares of the company’s stock valued at $1,001,000 after buying an additional 305 shares during the last quarter. UMB Bank n.a. lifted its stake in Ralliant by 49.6% during the 4th quarter. UMB Bank n.a. now owns 983 shares of the company’s stock valued at $50,000 after acquiring an additional 326 shares in the last quarter. Finally, Maryland State Retirement & Pension System lifted its stake in Ralliant by 1.5% during the 4th quarter. Maryland State Retirement & Pension System now owns 21,940 shares of the company’s stock valued at $1,117,000 after acquiring an additional 329 shares in the last quarter.

Insider Activity

In other news, SVP Karen M. Bick sold 6,062 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $72.00, for a total transaction of $436,464.00. Following the completion of the transaction, the senior vice president directly owned 31,668 shares of the company’s stock, valued at $2,280,096. This represents a 16.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Tamara S. Newcombe sold 12,936 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $71.79, for a total transaction of $928,675.44. Following the sale, the chief executive officer owned 251,967 shares of the company’s stock, valued at approximately $18,088,710.93. The trade was a 4.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.42% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on RAL. Oppenheimer upped their target price on shares of Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 13th. TD Cowen raised their price target on shares of Ralliant from $70.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Wall Street Zen upgraded shares of Ralliant from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 22nd. Morgan Stanley upped their price objective on shares of Ralliant from $68.00 to $85.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 23rd. Finally, Citigroup increased their price objective on shares of Ralliant from $81.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $75.70.

Ralliant Stock Down 2.6%

Shares of NYSE:RAL opened at $61.65 on Friday. The company has a market capitalization of $6.82 billion, a PE ratio of -5.68, a price-to-earnings-growth ratio of 2.35 and a beta of 1.60. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.52 and a quick ratio of 1.00. The business has a fifty day moving average price of $68.40 and a two-hundred day moving average price of $56.42. Ralliant Corporation has a 1 year low of $37.27 and a 1 year high of $75.41.

Ralliant (NYSE:RAL) last released its earnings results on Thursday, July 30th. The company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.05. The company had revenue of $567.80 million for the quarter. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Analysts forecast that Ralliant Corporation will post 2.87 earnings per share for the current year.

Ralliant Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Tuesday, September 8th will be given a $0.05 dividend. The ex-dividend date of this dividend is Tuesday, September 8th. This represents a $0.20 annualized dividend and a yield of 0.3%. Ralliant’s payout ratio is currently -1.84%.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.